Protocol Ledger

NCT06563895 · Phase III · RECRUITING

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Interventional Phase III clinical trial protocol NCT06563895 sponsored by Eidos Therapeutics, a BridgeBio company in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-12 Enrollment: 587 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06563895
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)587 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06563895
Protocol FieldVerified Registry Value
NCT IdentifierNCT06563895
Consolidated Lead SponsorEidos Therapeutics, a BridgeBio company
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment587 participants (ESTIMATED)
Registered Start Date2025-05-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI